Grassley Questions FDA’s Sanction of Blood Substitute Study Without Patient Consent
WASHINGTON – Sen. Chuck Grassley, chairman of the Committee on Finance, today
questioned why the Food and Drug Administration would allow a company to test a blood substitute
on trauma patients in 18 states without meaningful patient consent, with allegations of public safety
risks from the product, as reported in yesterday’s Wall Street Journal.
“If you’re in a car accident, of course you want emergency doctors to save your life,”
Grassley said. “But no reasonable person would expect to be treated as an experimental subject
without consent. The idea that the FDA would put the burden on the public to opt out of this mass
experiment is outrageous. Why should Americans have to wear a bracelet at all times to protect
themselves from a government-sanctioned medical experiment if they happen to get into a car
accident? I understand the value of a viable blood substitute, but I’m really disturbed by what I’m
hearing about the FDA’s role here and I want to find out what’s going on.”
The text of Grassley’s letter to the FDA follows.
February 23, 2006
Via Electronic Transmission
Dr. Andrew C. von Eschenbach
U.S. Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20857
Dear Dr. von Eschenbach:
The yellow “LIVESTRONG” wristband, promoted by the Lance Armstrong Foundation, is truly a
marketing phenomenon and a remarkably effective symbol on behalf of a noble cause – the battle
with cancer. It was no surprise to learn that you wear one. I write today, however, because I am
concerned about a far less popular and not widely worn wristband. If unsuspecting Americans were
aware of the import of this light-blue wristband, it might well be a marketing phenomenon, too. It
is outrageous that, for all intents and purposes, the FDA allowed a clinical trial to proceed, which
makes every citizen in the United States a potential “guinea pig,” without providing a practical,
informative warning to the public.
As a United States Senator representing the State of Iowa and as Chairman of the Committee on
Finance (Committee), which has jurisdiction over the Medicare and Medicaid programs, I am
responsible for oversight of matters that affect my constituents and the beneficiaries of these federal
health care programs. Accordingly, I have been persistent in my efforts to examine the performance
of the Food and Drug Administration (FDA) in recent years. Yesterday, the Wall Street Journal
(WSJ) ran an article entitled, “Amid Alarm Bells, A Blood Substitute Keeps Pumping,” that was
According to the article, the FDA is allowing a manufacturer, Northfield Laboratories, Inc., to test
its product, a blood substitute called PolyHeme, in a clinical trial (the PolyHeme Study) without the
consent of trauma patients, who often may be unconscious and/or otherwise incapable of providing
informed consent. The PolyHeme Study is being conducted pursuant to an infrequently used FDA
regulation, which allows for waiver of the informed consent typically required in clinical trials, if
some sort of community outreach program is implemented, among other requirements. It is the
community outreach that brings the light-blue wristbands into the mix.
For example, if you live in, next to, or travel through a state participating in the PolyHeme Study –
California, Colorado, Delaware, Georgia, Illinois, Indiana, Kansas, Kentucky, Michigan, Minnesota,
New York, North Carolina, Ohio, Pennsylvania, Tennessee, Texas, Utah, and Virginia – and you
suffer a traumatic injury and receive emergency medical treatment at a participating trauma center
in that state, you may, without your consent, become a human research subject for an experimental
blood product (if other contingencies are also met). That is, unless you happen to be wearing a lightblue
wristband imprinted with the following: “I decline the Northfield PolyHeme Study” (see
attached). I suspect many people, if they knew this, might reasonably ask, “where do I get my
It also comes as no surprise that this question is not a readily answerable one. Certainly, it’s not
apparent from any information on the FDA’s website. Nonetheless, an unknown number of
community meetings were reportedly held in the participating states. At these meetings, anyone who
knew of and took time to attend a meeting could opt out of the PolyHeme Study by requesting – and
wearing continuously for an undetermined period of time – one of these light-blue wristbands.
However, I am skeptical that any participating medical centers managed to conduct effective,
practical outreach to the community and to provide a meaningful, informative warning to the public
about the PolyHeme Study. Researchers in at least one state (Oregon) suspended participation in the
PolyHeme Study when it was unable to obtain local approval because the community meetings were
sparsely attended. According to a news report published in the Journal of Clinical Investigation in
July 2004, Loyola University Health System in Chicago engaged in an extensive effort to reach
potential participants in specific communities. However, the turnout at meetings was “surprisingly
low, averaging...between 0–5 people of those who responded.” The author of this news report raised
an important question: “Is this in absentia approval for the trial an inherent flaw in the initial
regulation whereby people, thinking they personally are unlikely to end up in the trial, don’t bother
with the outreach and are therefore not truly informed?”
Despite the recent media attention associated with the PolyHeme Study, more remains unknown than
known about it today. Accordingly, as Chairman of the Committee, I request that the FDA address
this issue by providing the public with meaningful information related to what it should already have
known about the PolyHeme Study. In addition, at the earliest opportunity, but no later than March
8, 2006, please provide my Committee with a detailed briefing regarding the PolyHeme Study. Over
the next few days, my Committee staff will contact your staff with more specific requests for
information, but at the minimum your staff should be prepared to address the following issues related
to the PolyHeme Study:
1. What oversight, if any, has FDA conducted related to the PolyHeme Study?
2. What consultation with representatives of the community was conducted?
3. What public disclosure to communities was conducted prior to initiation of the PolyHeme Study?
4. Were known adverse events, including but not limited to those reported in the WSJ, disclosed with
the risks and expected benefits information?
5. Has Northfield Laboratories, Inc., met all regulatory reporting requirements related to its
PolyHeme product, including but not limited to timely reporting of all adverse events?
Finally, I request a detailed list and summary of all clinical trials, between January 1, 1996, and the
date of this request, conducted pursuant to the FDA regulation governing exception from informed
consent requirements for emergency research.
Thank you in advance for having your staff contact my Committee staff by March 1, 2006, to
coordinate this briefing.
Charles E. Grassley
United States Senator
Next Article Previous Article
- Senate Finance Republicans: IRS Document Destruction Harmed Taxpayers
- Government Watchdog Says IRS Needs to Address Critical Safeguard Weaknesses
- Crapo Statement at Taiwan Tax Legislation Markup
- Pandemic Unemployment Fraud Estimates Double to $100-$135 Billion; Crapo, Smith Call for Action
- Fact Sheet: Democrats’ Drug Price-Setting Scheme Dismantles Medicare’s Promise, Undermines Seniors’ Health